← boothcheck

Is DOCS overvalued?

boothcheck doesn't label DOCS overvalued or undervalued, and it doesn't publish a fair value. It shows what the price assumes instead. At today's price, DOCS is priced for growth of +17.7%, and an operating margin near 9.5% versus the 40.4% it earns today. The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price. The more the price assumes beyond what Doximity, Inc. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from Doximity, Inc.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 27, 2026.

Implied growth+17.7%
For about
Margin needed9.5%
Margin today40.4%
Price vs asset value1.77x
Price vs earnings power1.96x
Price vs peer multiples0.74x
Price vs forward growth0.70x
Read the full DOCS report →
Get boothcheck's read on what DOCS's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.